Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia

International Clinical Psychopharmacology

Volumn 28, Issue 4, 2013, Pages 171-176

  Wolfgang Fleischhacker, W ^a   Sanchez, Raymond ^b   Johnson, Brian ^b   Jin, Na ^c   Forbes, Robert A ^b   McQuade, Robert ^b   Baker, Ross A ^b   Carson, William ^b   Kane, John M ^d  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^c Otsuka Pharmaceutical Development and Commercialization Inc   (United States)

^d ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

aripiprazole; long acting injection; safety; schizophrenia; tolerability

Indexed keywords

AMANTADINE; ARIPIPRAZOLE; BENZATROPINE; BIPERIDEN; DEXETIMIDE; ESZOPICLONE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LORAZEPAM; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METIXENE; ORPHENADRINE; PLACEBO; PROCYCLIDINE; PROPRANOLOL; TRIACYLGLYCEROL; TROPATEPINE; ZALEPLON; ZOLPIDEM; ZOPICLONE;

ADULT; AKATHISIA; ANXIETY DISORDER; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSOMNIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EARLY TERMINATION OF CLINICAL TRIALS; HUMANS; INCIDENCE; INJECTIONS, INTRAMUSCULAR; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA; SLEEP INITIATION AND MAINTENANCE DISORDERS; WEIGHT GAIN; YOUNG ADULT;

EID: 84879960353     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e3283615dba     Document Type: Article

References (19)

1. Barnes TR (1989). A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676. (Pubitemid 19154942)
2. Croxtall JD (2012). Aripiprazole: a review of its use in the management of schizophrenia in adults. CNS Drugs 26:155-183.
3. Fleischhacker WW, McQuade RD, Marcus RN, Archibald D, Swanink R, Carson WH (2009). A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry 65:510-517.
4. Guy W(1976). Abnormal Involuntary Movement Scale (AIMS). US Department of Health Education and Welfare. ECDEU assessment manual for psychopharmacology. Rockville, MD: National Institute of Mental Health.
5. Kane J, Sanchez R, Perry P, Jin N, Johnson B, Forbes R, et al. (2012). Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week multicenter, randomized, double-blind, placebo-controlled. J Clin Psychiatry 73:617-624.
6. Kane JM (2011). Improving treatment adherence in patients with schizophrenia. J Clin Psychiatry 72:e28.
7. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW (2002). Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63:763-771.
8. Kane JM, Barnes TR, Correll CU, Sachs G, Buckley P, Eudicone J, et al. (2010). Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short-and longterm aripiprazole trials. J Psychopharmacol 24:1019-1029.
9. Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, et al. (2003). Efficacy and safety of aripiprazole versus haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 6:325-337. (Pubitemid 38146250)
10. Keck PE, Calabrese J, McQuade RD, Carson W, Carlson BX, Rollin LM, et al. (2006). A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 67:626-637. (Pubitemid 43764240)
11. Keck PE Jr, Calabrese JR, McIntyre RS, McQuade RD, Carson WH, Eudicone JM, et al. (2007). Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 68:1480-1491. (Pubitemid 350073394)
12. Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S (2011). Oral versus depot antipsychotic drugs for schizophrenia-a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 127:83-92.
13. Macfadden W, Ma YW, Thomas Haskins J, Bossie CA, Alphs L (2010). A prospective study comparing the long-term effectiveness of injectable risperidone long-acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry (Edgmont) 7:23-31.
14. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, et al. (2003). Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 61:123-136. (Pubitemid 36513927)
15. Miller CH, Fleischhacker WW (2000). Managing antipsychotic-induced acute and chronic akathisia. Drug Saf 22:73-81. (Pubitemid 30058028)
16. Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG (2003). Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 64:1048-1056. (Pubitemid 37158250)
17. Simpson GM, Angus JW (1970). A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11-19.
18. Simpson GM, Mahmoud RA, Lasser RA, Kujawa M, Bossie CA, Turkoz I, et al. (2006). A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 67:1194-1203. (Pubitemid 44439690)
19. Taylor D (2009). Psychopharmacology and adverse effects of antipsychotic longacting injections: a review. Br J Psychiatry 52:S13-S19.